Glaxosmithkline Consumer Nigeria Plc 2023 Interim Results For The Half Year

Glaxosmithkline Consumer Nigeria Plc (GLAXOS.ng) HY2023 Interim Report

By Published On: August 3, 2023TYPE: Interim ReportsYear: 2023Period: HYCountry: NigeriaSector: Pharmaceuticals

Glaxosmithkline Consumer Nigeria Plc (GLAXOS.ng) listed on the Nigerian Stock Exchange under the Pharmaceuticals sector has released its 2023 interim results for the half year.

For more information about Glaxosmithkline Consumer Nigeria Plc (GLAXOS.ng) reports, abridged reports, interim earnings results and earnings presentations visit the Glaxosmithkline Consumer Nigeria Plc (GLAXOS.ng) company page on AfricanFinancials.

Indicative Share Trading Liquidity

The total indicative share trading liquidity for Glaxosmithkline Consumer Nigeria Plc (GLAXOS.ng) in the past 12 months, as of 3rd August 2023, is US$1.31M (NGN671.64M). An average of US$109.25K (NGN55.97M) per month.

Glaxosmithkline Consumer Nigeria Plc 2023 interim results for the half year

Company Profile

Glaxosmithkline Consumer Nigeria Plc manufactures and markets a range of consumer healthcare and pharmaceutical products in Nigeria. Its product portfolio includes treatments for asthma, HIV/AIDS, malaria, depression, migraines, diabetes, heart failure, digestive ailments and cancer. Consumer healthcare products include oral healthcare products; wellness products for the management of pain, gastro-intestinal and respiratory conditions; multivitamins; and a range of nutritional healthcare beverages. Glaxosmithkline Consumer Nigeria Plc produces a range of antibacterial products and vaccines to protect against illnesses such as hepatitis A and B, diphtheria, tetanus, whooping cough, typhoid, influenza and cervical cancer. The company was formerly known as Beecham Limited. Its head office is in Lagos, Nigeria. Glaxosmithkline Consumer Nigeria Plc is listed on the Nigerian Stock Exchange